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ABSTRACT
Through the years, different studies showed the involvement of Protein Kinase C 
(PKC) in cell cycle control, in particular during G1/S transition. Little is known about 
their role at G2/M checkpoint. In this study, using K562 human erythroleukemia 
cell line, we found a novel and specific mechanism through which the conventional 
isoform PKCa positively affects Cyclin B1 modulating G2/M progression of cell cycle. 
Since the kinase activity of this PKC isoform was not necessary in this process, we 
demonstrated that PKCa, physically interacting with Cyclin B1, avoided its degradation 
and stimulated its nuclear import at mitosis. Moreover, the process resulted to be 
strictly connected with the increase in nuclear diacylglycerol levels (DAG) at G2/M 
checkpoint, due to the activity of nuclear Phospholipase C β1 (PLCβ1), the only PLC 
isoform mainly localized in the nucleus of K562 cells. Taken together, our findings 
indicated a novel DAG dependent mechanism able to regulate the G2/M progression 
of the cell cycle.
INTRODUCTION
Protein kinase C (PKC) is a family of serine/
threonine kinases involved in different biological 
functions [1–3]. Ten PKCs are present in mammalian 
cells and are divided in three classes based on their 
structure domains and activation [1–3]. Indeed, activation 
of conventional PKCs (PKCα, βI, βII and γ) requires 
the lipid second messengers diacylglycerol (DAG) and 
Ca2+, while novel isozymes (PKC δ, ε, θ and η) need only 
DAG. On the contrary, the atypical class (PKCζ and λ/ι) 
is not sensible to any of them, and its activation is due to 
protein-protein interactions [1–3]. Our knowledge about 
the involvement of these enzymes in cell cycle regulation 
is very wide at the moment and, through the years, it 
became clear that these effects are linked to the different 
contexts where they take place [2–4]. As a matter of fact, 
many studies reported roles for PKCs in cell cycle both as 
anti-proliferative and growth-stimulatory enzymes [2–5]. 
Modulation of cell proliferation by PKCs is characterized 
by high complexity, effecting different molecules involved 
in the control of the cell cycle including cyclins, cyclin-
dependent kinases (Cdk), Cip/Kip inhibitors and Lamins 
[2, 4–8]. However, several evidences indicated Cip/Kip 
inhibitors and D-type cyclins as the most frequent targets 
for PKCs. Indeed, many studies described the involvement 
of PKCs in G1/S transition regulating Cyclin D1, p21/
Cip1 or p27/Kip1 expressions in different cell lines 
[2, 4, 8–11]. Recently, we found that PKCα was 
necessary in PLCβ1 mediated regulation of Cyclin D3 
and cell proliferation in human erythroleukemia cells 
[12, 13]. On the other hand, little is known about the 
role of PKCs at G2/M phase [2, 4]. Different studies 
showed their peculiar ability to partially translocate 
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into the nuclei influencing this phase of the cell cycle. 
In particular, nuclear import of PKCs was correlated to 
the increase of nuclear diacylglycerol (DAG) before 
mitosis [6] [14] [15–18]. These findings were supported 
by Fiume et. al, who demonstrated that PKCα, once in 
the nuclei, could phosphorylate Lamin B1 stimulating 
lamin dissociation and G2/M progression [19]. In this 
study, investigating other possible roles for PKCs at 
G2/M phase, we found that Cyclin B1 can positively be 
modulated by PKCα. As widely described in literature, 
the entry of eukaryotic cells into mitosis is due to the 
activation of cyclin dependent kinase 1 (Cdk1), which 
complexes with its regulatory subunit Cyclin B1 to 
form the mitosis-promoting factor (MPF) [21–28]. MPF 
remains inactive until Cdk1 is phosphorylated at Thr161 
by Cdk activating kinase (CAK) and de-phosphorylated by 
Cdc25c at Thr14/Thr15 [20–28]. In addition, Cyclin B1 is 
phosphorylated by Cdk1 and Polo-like kinase 1 (PLK1) 
in its cytoplasmic retention signal (CRS) domain, which 
regulates its nuclear translocation at late prophase 
[21–28]. This nuclear accumulation has been highly 
studied and described, but remains not completely 
understood for the lack of a canonical nuclear localization 
signal (NLS) in Cyclin B1 structure, usually necessary for 
nuclear import through the karyopherins system [21–29]. 
However, once in the nuclei, Cyclin B1/Cdk1 complex 
phosphorylates a wide number of substrates driving 
the cells into mitosis [20–28]. Finally, at the end of the 
mitotic process, Cyclin B1 starts to be degraded by the 
APC/C complex and Cdk1 undergoes inactivation leading 
cells to mitotic exit and cytokinesis [21–32]. Here, we 
describe, for the first time, a DAG dependent mechanism 
linking PKCα to Cyclin B1 at G2/M checkpoint. Indeed, 
investigating whether PKCs could affect G2/M progression 
in K562 cell line, we found that Cyclin B1 was positively 
modulated by PKCα. This event was independent of the 
kinase activity of the enzyme. Moreover, PKCα resulted 
to physically interact with Cyclin B1 during cell cycle 
progression, avoiding its degradation and promoting its 
nuclear accumulation. Finally, we observed how DAG 
accumulation in nucleus, due to the activity of nuclear 
PLCβ1, could modulate Cyclin B1 and PKCα nuclear 
translocation at G2/M checkpoint.
RESULTS
PKCs affect Cyclin B1 levels in K562 cells
In order to find whether PKCs could target Cyclin B1 
expression during cell cycle of K562 cell line, we 
treated cells with three different PKC inhibitors at 
a final concentration of 1μM: Go6983, Go6976 and 
3-(1-(3-imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-
1H-pyrrole-2,5-dione anilinomonoindolylmaleimide 
(from here simply PKC inhibitor) [1, 2, 19] [33, 34]. 
Next, we synchronized the cells at G2/M checkpoint using 
Nocodazole (20ng/ml) for 16 hours to avoid any cell cycle-
dependent modulation of Cyclin B1 expression. Notably, 
immunoblot analyses showed an important decrease of 
Cyclin B1 levels only in cells treated with PKC inhibitor. 
The effect appeared to be concomitant with the high 
reduction of PKCα and PKCβII, the only two conventional 
PKC isoforms expressed in our model [12, 35, 36]. This 
down-modulation of the level of PKCs was not linked to 
their reduced gene expression (Supplementary Figure 1) 
but, probably, to side effects on other enzymes involved 
in PKC regulation. On the contrary, using Go6976 and 
Go6983, which inhibited only PKC activity [33], we 
did not observe any appreciable change in Cyclin B1 
expression. In addition, we stimulated PKC signalling 
using Phorbol-12-Myristate-13-Acetate (PMA) at a 
final concentration of 50nM for 16 hours. Interestingly, 
synchronized K562 cells at G2/M checkpoint showed an 
important decrease of Cyclin B1 parallel to PKCα and 
PKCβII degradation. PKCs degradation was probably 
due to their hyper-activation by PMA [35–37], Cyclin B1 
down-modulation seemed to be related to the decrease of 
PKCs in the cells as well as during treatments with PKC 
inhibitor (Figure 1A).
PKCα is the conventional isoform that modulates 
Cyclin B1 affecting cell cycle progression
In order to understand which of the two 
conventional PKC isoforms was responsible of the 
phenomenon described above, we transiently silenced 
both of them using RNA interference techniques 
(PKCα KD/PKCβII KD). More than one siRNA was 
used for the experiments in order to exclude any off-
target effects and no changes in the results were found 
(see materials and methods). A Scrambled siRNA was 
used as control (Scrambled). 24 hours after transfection, 
using Nocodazole, we synchronized the cells at G2/M 
checkpoint. Here, we observed a strong down-regulation 
of Cyclin B1 only in cells characterized by PKCα knock-
down. PKCβII did not affect it at all (Figure 1B). Next, 
to confirm that this modulation was due to a specific 
effect of PKCα on Cyclin B1, we screened other proteins 
related to G2/M progression. None of these molecules was 
affected (Supplementary Figure 2). In addition, we also 
investigated if PKCα could be responsible for Cyclin B1 
phosphorylations, including Ser133 and Ser147, but 
it was not (Supplementary Figure 2). However, we 
found that this specific modulation of Cyclin B1 could 
affect cell cycle progression. In order to investigate 
these effects, we silenced PKCα and we synchronized 
the cells at G2/M. Then, we removed Nocodazole, 
we washed the cells in PBS and we seeded them again 
in complete RPMI 10% FBS. 24 hours later, cell cycle 
analyses indicated that PKCα silencing drove the cells to 
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Figure 1: Protein kinase C α (PKCα) involvement in Cyclin B1 regulation. (a) K562 cells were treated with three different 
PKC inhibitors (PKC inhibitor, Go6983, Go6976) and with phorbol-12-myristate-13-acetate (PMA). Cells were synchronized at G2/M by 
Nocodazole. PKCs decrease led to a severe downregulation of Cyclin B1 expression if compared to the controls (Control). (b) PKCα and 
PKCβII were silenced for 48 hours (PKCα KD/PKCβII KD). Cells were synchronized at G2/M using Nocodazole. A scrambled siRNA 
was used as control (Scrambled). Only PKCα silencing drove to Cyclin B1 downmodulation. The silencing was performed using different 
siRNAs to avoid any possible off-target effects. (c) Cells, blocked at G2/M, were seeded again in complete RPMI 10% FBS. 24 hours later, 
cell cycle analysis was performed indicating an accumulation at G2/M in PKCα knock-down conditions. (d) PKCα was overexpressed 
using a Wild Type (PKCα OV WT) or a Dominant Negative (PKCα OV DN) vector. Cells were stimulated to accumulate at G2/M using 
Nocodazole for 6 hours. Empty vector was used as control (Empty). Overexpression of PKCα WT and DN lead to an upmodulation of 
Cyclin B1. (e) Cells were treated using Nocodazole as in d) and cell cycle analysis was performed indicating an higher accumulation at 
G2/M of cells overexpressing PKCα.
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a higher G2/M accumulation compared to the controls. 
This could be related to the lack of Cyclin B1 caused by 
PKCα silencing. Indeed, accordingly to literature, a high 
decrease of Cyclin B1 could interfere with the transition 
through the G2/M phase of cell cycle [38]. Moreover, the 
same experiments were performed using PKC inhibitor, 
whose effects on cell cycle were stronger but very similar 
to PKCα silencing (Supplementary Figure 3). Finally, 
we analyzed proliferation of K562 cell line. We silenced 
PKCα and, 24 hours later, we synchronized the cells using 
Nocodazole. Then we removed the G2/M block seeding 
the transfected cells in complete RPMI 10% FBS at a 
cell density of 10 × 105/ml. Experiments of cell counting, 
performed for 72 hours, showed that PKCα silencing did 
slow-down cell proliferation of K562 cells compared to 
the controls. The same effects were noticed using PKC 
inhibitor (Supplementary Figure 4).
PKCα activity was not necessary  
for Cyclin B1 modulation
Since PKCα positively modulated Cyclin B1 levels 
in K562 cells, we decided to investigate if its kinase 
activity was necessary to this process. Then, we transiently 
overexpressed PKCα using two different vectors, a Wild 
Type vector (PKCα OV WT) and a Dominant Negative 
mutant (PKCα OV DN). Empty vector (Empty) was 
used as control. 24 hours after the transfections, we 
added Nocodazole for 6 hours to drive the cells to 
G2/M. This partial synchronization was performed to 
stimulate Cyclin B1 accumulation and study if PKCα 
overexpression could promote this process. Notably, in 
cells characterized by PKCα WT or DN overexpression, 
we found the same increase of Cyclin B1 compared to the 
controls (Figure 1D). As a further proof that the kinase 
activity of PKCα was not necessary in this process, we 
analyzed cell cycle of these samples. Overexpression 
of the two PKC vectors, WT and DN, led the cells to 
a quicker accumulation at G2/M than the controls. 
In addition, cell counting analyses demonstrated that 
up-modulation of PKCα was able to increase K562 cell 
proliferation (Supplementary Figure 4). Taken together, 
these data suggested that the kinase activity of PKCα was 
not necessary in Cyclin B1 modulation.
Lack of PKCα leads to a faster degradation 
of Cyclin B1 in K562 cell line
In order to deeply understand how PKCα could 
affect Cyclin B1, we decided to investigate at which 
level this modulation took place. We silenced or 
overexpressed PKCα and we synchronized K562 cells 
as previously described. We performed gene expression 
analyses of Cyclin B1, but we did not find any changes 
in its expression levels (Figure 2A). These evidences 
suggested the existence of a post-transcriptional effect 
on Cyclin B1 by PKCα. Then, we focused our studies 
on Cyclin B1 degradation, implying a possible role for 
PKCα as a scaffold molecule. As already reported [30, 31], 
Cyclin B1 undergoes degradation at the end of mitosis. 
Thus, we used a proteasome inhibitor, MG-132, to block 
protein degradation after G2/M release. Our findings 
showed that treating K562 cells with MG-132 up to two 
hours, at a final concentration of 15μM, blocked Cyclin 
B1 degradation driving to its accumulation in the cells 
(Supplementary Figure 5). Then, we silenced PKCα 
and, 48 hours later, we divided transfected cells in two 
aliquots; one was treated with MG-132 for two hours, one 
was seeded in complete RPMI 1640 10% FBS and used as 
control. Notably, MG-132 treated cells showed a peculiar 
and significant increase of Cyclin B1 levels compared to 
the control. PKCα expression remained silenced in both 
samples (Figure 2B). These evidences indicated that the 
presence of PKCα inhibited the degradation of Cyclin B1 
in K562 cells. In addition, as a positive control, we decided 
to investigate the Cip inhibitor p21 [39], already described 
to highly accumulate during Cyclin B1 degradation [40]. 
Interestingly, in cells transfected to silence PKCα, the 
decrease of Cyclin B1 was concomitant with an important 
up-modulation of p21/Cip1 levels (Figure 2C). Taken 
together, these data supported our theory, showing that 
lack of PKCα drove to a faster degradation of Cyclin B1 
in K562 cells.
Cyclin B1 and PKCα interact  
during cell cycle progression
In this series of experiments, we focused on the 
expression and localization of Cyclin B1 and PKCα 
during cell cycle progression. Then, we treated our cells 
to promote their accumulation in the desired cell cycle 
phases. In particular, we starved K562 cells, using HBSS 
for 16 hours, to obtain a G0-G1 synchronization (G0-G1). 
G1/S phase was referred to proliferating cells in normal 
and complete RPMI 1640 10% FBS (G1/S). Finally, 
using Nocodazole, we obtained a G2/M block (G2/M) 
(Figure 3A). Firstly, immunoblot analyses showed a 
progressive increase of Cyclin B1 and PKCα expression 
through the cell cycle peaking at G2/M. Next, separating 
nuclei of K562 cells from the cytoplasms, we investigated 
their localization along the different phases. Notably, PKCα 
accumulated in the nucleus especially in G2/M cells as 
well as Cyclin B1 (Figure 3B). This similar co-localization 
was also confirmed by immunocytochemistry analyses 
(Figure 3C). Next, we decided to see if these two proteins 
could interact during cell cycle. After seeing that our 
immunoprecipitation experiments worked properly (Figure 
3D), we synchronized the cells at G2/M checkpoint and 
we performed co-immunoprecipitation analyses to seek 
the possible formation of complexes between the two 
enzymes. Interestingly, our findings showed that PKCα 
and Cyclin B1 could interact (Figure 3D). As in the 
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negative control (IgG) of PKCα immunoprecipitation 
appeared a partial non-specific band, probably due to 
cross-reaction between the antibody, we repeated the 
experiments more than 4 times. Moreover, interaction 
between the two proteins was detected also in G1/S 
cycling cells, which confirmed the capacity of PKCα 
and Cyclin B1 to complex during cell cycle progression 
(Supplementary Figure 6). Next, in order to further 
investigate the existence of this complex, we again 
immunoprecipitated PKCα and we found it was able to 
interact with cdk1/cdc2, the kinase that forms the MPF 
associating with Cyclin B1 [20–25], [26], [27, 28]. As 
positive control of the experiment, we immunoprecipitated 
Cyclin B1 finding it perfectly complexed with cdk1/
cdc2 (Figure 3E). Finally, we repeated these experiments 
separating nuclei from cytoplasms of cells synchronized at 
Figure 2: Lack of PKCα drives to a faster degradation of Cyclin B1. (a) Gene expression analyses of Cyclin B1 in conditions 
of silencing or overexpression of PKCα. Cells were synchronized at G2/M. Cyclin B1 expression is not affected by modulation of PKCα. 
(b) PKCα was silenced and, 48 hours later, transfected cells were divided in two aliquots: one used as control (PKCα KD) and one treated 
with MG-132 for 2 hours (PKCα KD + MG-132 2h) The treatment blocked Cyclin B1 degradation and led to its accumulation in the cells. 
No changes in PKCα levels were detected. These evidences suggested that down-modulation of Cyclin B1 due to lack of PKCα was ceased 
inhibiting the proteasome machinery. (c) PKCα was silenced and cells synchronized at G2/M. Silencing of PKCα (PKCα KD) leads to 
an accumulation of p21 compared to the control (Scrambled). This effect is opposite to Cyclin B1 decrease. p21 was used as a marker of 
degradation for Cyclin B1.
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Figure 3: PKCα and Cyclin B1 accumulate into the nuclei and interact at G2/M. (a) Cells were synchronized in G0/G1 by 
HBSS (G0/G1), G1/S by complete RPMI 10% FBS (G1/S) and G2/M by Nocodazole (G2/M). (b) Immunoblot analysis of total, nuclear and 
cytoplasmic lysates of cells synchronized at different cell cycle phases was performed to investigat PKCα and Cyclin B1 expression and 
localization during cell cycle. PKCα and Cyclin B1 increase and translocate into the nuclei during cell cycle, peaking at G2/M checkpoint. 
(c) Cells were synchronized as a) and analyzed using immunocytochemistry to study PKCα and Cyclin B1 localization. The two enzymes 
co-localize during cell cycle progression and accumulate into the nuclei in particular at G2/M transition.
(Continued)
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G2/M and we found that Cyclin B1 and PKCα were able 
to interact in the cytoplasmic fraction (Figure 3F). These 
data indicated that the interaction between the two proteins 
could be very important in the prevention of Cyclin B1 
degradation during cell cycle progression.
Cyclin B1 nuclear accumulation is modulated by 
the changes of PKCα expression
As reported above, PKCα and Cyclin B1 co-localize 
and interact, in particular during G2/M progression. Both 
of these molecules can accumulate into the nucleus during 
this phase of the cell cycle, but how this mechanism 
works is still not well understood [24]. In these series of 
experiments, we showed that lack or increase of PKCα, 
and its consequent minor or major nuclear translocation 
at mitosis, affected Cyclin B1 nuclear import. We silenced 
or overexpressed PKCα in cells treated with Nocodazole 
as previously described and we separated nuclei from 
cytoplasms. Silencing of PKCα led to a decrease of 
Cyclin B1 levels in cytoplasms and in nuclei of K562 
cells synchronized at G2/M checkpoint (Figure 4A). On 
the contrary, overexpression of PKCα drove to a higher 
accumulation of Cyclin B1 both into the nuclear and 
cytoplasmic fractions (Figure 4B). All these data were 
confirmed by immunocytochemistry experiments and 
using PKC inhibitor (Figure 4C and Supplementary 
Figure 7A and 7B). Taken together, these evidences 
indicated that the more PKCα translocates in the nucleus 
at G2/M checkpoint the more nuclear accumulation of 
Cyclin B1 takes place in K562 cell line.
Nuclear DAG increase is required for PKCα and 
Cyclin B1 translocation into the nucleus
In order to better understand the mechanism by 
which PKCα and Cyclin B1 accumulate into the nucleus 
at G2/M checkpoint, we investigated nuclear DAG 
fluctuations during cell cycle progression of K562 cells. As 
already reported, nuclear amount of DAG peaks at G2/M, 
attracting PKCs to translocate into the nucleus [6, 15, 17]. 
Cells were synchronized at G1/S and G2/M as previously 
described. Total and nuclear samples were labeled with 
[3H]-glycerol and lipids were extracted. The percentage 
of radioactivity corresponding to DAG was analyzed 
(see materials and methods for the complete protocol). 
Accordingly with other studies [6, 15, 17], we found a 
slight increase in DAG levels in total samples of cells 
synchronized at G2/M compared to G1/S cells. On the 
other hand, analyzing nuclear extracts, we observed a very 
high increase in nuclear DAG in G2/M cells compared to 
G1/S cells (Figure 5A). This evidence suggested DAG as 
the molecule responsible for Cyclin B1 and PKCα nuclear 
translocation. Then, in order to simulate DAG effects 
on PKCα nuclear import, we treated the cells with PMA 
(100nM) for 30 minutes, as already described [41, 42]. 
Nuclear fractions of G2/M cells treated with PMA showed 
an increase of Cyclin B1 and PKCα levels compared to 
Figure 3: (d) Co-immunoprecipitations experiments in cells synchronized at G2/M (G2/M) indicated the possibility for PKCα 
and Cyclin B1 to complex. As negative control non-specific IgG were used (IgG). 50μg total lysate of K562 were used as 
positive control (Control +). To show that the experiments were performed correctly, immunoblots of the immunoprecipitated 
proteins are provided. All the experiments were performed more than four times. (e) Cells were blocked at G2/M checkpoint 
and PKCα or Cyclin B1 were immunoprecipitated. An antibody anti-cdk1/cdc2 was used to detect the capacity for both the 
proteins to interact with this kinase. (f) The interaction between Cyclin B1 and PKCα takes place in the cytoplasms. Nuclei 
and cytoplasms of cells synchronized in G2/M were separated. Cyclin B1 was immunoprecipitated and PKCα was detected 
via Western Blotting. The complex between the two enzymes was appreciable only in the cytoplasmic fractions of the cells. 
The experiment was repeated three times as shown in the figure.
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the controls. However, as known, DAG is the product of 
the action of the Phospholipases C (PLC) activity, which, 
hydrolyzing Phosphatidylinositol 4, 5-bisphosphate (PIP2), 
produces DAG and Inositol triphosphate (IP3) [43–45]. 
Thus, in order to reduce DAG production, we treated 
our cells with a potent PLC inhibitor, U73122, at a final 
concentration of 10μM for 16 hours. Nuclear amount of 
PKCα in G2/M synchronized cells was analyzed. We 
found a strong decrease of nuclear PKCα in cells treated 
with U73122 compared to the controls. Notably, Cyclin B1 
nuclear accumulation was inhibited too (Figure 5B). Taken 
together, these data indicated DAG as an important factor 
for nuclear import of PKCα, which, in turn, seemed to 
stimulate Cyclin B1 nuclear accumulation during G2/M 
progression.
Nuclear PLCβ1 is responsible for DAG 
regulation during cell cycle progression
In this series of experiments, we screened some of 
the most expressed PLC isoforms in K562 cells, in order 
to understand which one was responsible for nuclear DAG 
oscillations during cell cycle. Then, we synchronized the 
cells at the different phases of cell cycle and we separated 
nuclei from cytoplasms. Interestingly, among the PLC 
isoforms studied, only PLCβ1 resulted mainly localized 
Figure 4: PKCα silencing or overexpression modulate the amount of Cyclin B1 in the nucleus at G2/M checkpoint. 
(a) PKCα was silenced and, 48 hours later, cells were synchronized using Nocodazole. A Scrambled siRNA was used as control (Scrambled).
Then, nuclei and cytoplasms were separated and Cyclin B1 localization was investigated. Cyclin B1 decreases both in the cytoplasms and 
in the nuclei. (b) PKCα was overexpressed using WT and DN vectors and cells were treated with Nocodazole for 6 hours. An Empty vector 
(Empty) was used as control. Cyclin B1 increases both in the nuclei and the cytoplasms. (c) Cells were treated as reported in a) and b) and 
immunocytochemistry was performed to study the localization of Cyclin B1.
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Figure 5: PLCβ1 related nuclear DAG increase at G2/M stimulates nuclear translocation of PKCα and 
Cyclin B1. (a) Cells were synchronized at G1/S and G2/M and nuclear or total samples were treated to extract lipids. The percentage of 
radioactivity corresponding to DAG amount was investigated. Nuclear DAG increased at G2/M. (b) Cells were treated with PMA (PMA) 
or U73122 (U73122) and synchronized at G2/M. Nuclear accumulation of PKCα and Cyclin B1 resulted linked to DAG fluctuations during 
cell cycle. (c) Cells were synchronized at G0/G1, G1/S and G2/M and the localization of different PLCs was investigated. PLCβ1 was 
the only one mainly localized into the nucleus. (d) Immunocytochemistry was performed to further study PLCβ1 localization. (e) PLCβ1 
was silenced (PLCβ1 KD) and cells were synchronized at G2/M. A Scrambled siRNA was used as control (Scrambled). PKCα and Cyclin 
B1 had minor nuclear accumulation in PLCβ1 knock-down conditions. (f) PLCβ1 (PLCβ1 KD), PKCα (PKCα KD) or both the molecules 
(PLCβ1 KD – PKCα KD) were silenced. After synchronization at G2/M phase, immunoblot analyses showed that double knock-down 
condition had the same effects on Cyclin B1 expression than PKCα silencing alone. PLCβ1 silencing did not affect Cyclin B1. 
(Continued)
Oncotarget11535www.impactjournals.com/oncotarget
into the nucleus of K562 cells (Figure 5C-D). Next, we 
transiently silenced PLCβ1 (PLCβ1 KD) and, 48 hours 
later, we synchronized the cells at G2/M checkpoint. 
We used more than a single siRNA to silence PLCβ1 
expression to avoid any possible off-target effect and 
the experiments were repeated more than three times 
(see materials and methods). Notably, we observed a minor 
accumulation of both PKCα and Cyclin B1 in PLCβ1 
knock-down cells compared to the controls (Scrambled) 
(Figure 5E). Moreover, PLCβ1 and PKCα resulted 
to be part of the same pathway. We silenced PLCβ1 
(PLCβ1 KD), PKCα (PKCα KD) or both the molecules 
(PLCβ1 KD – PKCα KD). A Scrambled siRNA was used 
as control (Scrambled). 48 hours after the transfections, 
cells were synchronized at G2/M. Interestingly, double 
knock-down of PKCα and PLCβ1 had the same effects on 
Cyclin B1 expression than the silencing of PKCα alone. 
In addition, PLCβ1 silencing did not affect Cyclin B1 
(Figure 5F). Finally, in order to further confirm that PLCβ1 
silencing reduced its nuclear activity and, therefore, the 
production of DAG, we analyzed the production of 
IP3 in nuclear lysates of G2/M cells using a PLC assay 
previously described [46]. According to our findings, 
nuclear fractions characterized by PLCβ1 knock-down 
showed a strong decrease in IP3 amount compared to the 
controls (Figure 5G). These findings demonstrated the 
importance of nuclear PLCβ1 for the oscillations of DAG, 
related to the different cell cycle phases.
DISCUSSION
Although the involvement of Protein Kinases C 
in the regulation of cell cycle progression has already 
been widely investigated, little has been reported about a 
possible connection between PKC signalling and Cyclin 
B1/Cdk1. In particular, even if other classes of Cyclins 
(D, E and A) can be modulated by different isoforms of 
PKCs, Cyclin B1 was not linked to any of them so far 
[2, 4, 12, 47]. Previous studies from our laboratory 
indicated important roles for PKCα in cell cycle regulation. 
As a matter of fact, we found that PKCα was able to 
translocate into the nuclei of murine erythroleukemia 
cells (MEL) at the beginning of mitosis [19]. Here, it 
phosphorylated Lamin B1, stimulating its disassembly 
and, then, the progression through G2/M phase. More 
recently, we demonstrated that lipid signalling could be 
involved in the regulation of Cyclin D3 and, in turn, of 
cell proliferation in human erythroleukemia cells, K562. 
Indeed, we observed that overexpression of PLCβ1 drove 
to an up-modulation of Cyclin D3 and a down-regulation 
of PKCα expression [12]. This was followed by an 
accumulation of cells at G1/S transition. In particular, 
silencing of PKCα led to a very similar up-regulation 
of Cyclin D3 compared to PLCβ1 overexpression [12]. 
Taken together, these evidences suggested an important 
role for PKCα in cell cycle modulation of K562 cell 
line. Moreover, as up-modulation of D-type cyclins 
is commonly linked to down-regulation of the B-type 
isoforms, we decided to understand if PKCα could be also 
involved in G2/M progression targeting Cyclin B1 [21]. 
In this study, we described a novel and peculiar DAG-
dependent mechanism through which PKCα regulates 
Cyclin B1, leading to effects on G2/M transition. Indeed, 
using different PKC inhibitors, we observed a strong 
decrease of Cyclin B1 expression consequent to PKCs 
down-regulation. Notably, inhibiting only the activity of 
PKCs, we did not find any effect on Cyclin B1 expression. 
As the effects of two of the inhibitors that we used, 
Go6976 and Go6983, have already been widely described 
in literature [33], surprising was the capacity of the PKC 
inhibitor to downregulate the levels of conventional PKCs 
in our cell model (at 1μM it seemed not specific only for 
PKCβ, see materials and methods). As the gene expression 
of the enzymes was not targeted, this peculiar action on 
PKCs was probably due to side effects on other proteins 
involved in PKC life cycle. However, this mechanism 
must be further studied in the future. Moreover, 
treating the cells with PMA, in order to stimulate the 
PKC signalling, we obtained, a strong decrease in PKC 
expression, followed by a drop of Cyclin B1 levels. If PKC 
Figure 5: (g) PLCβ1 was silenced and cells synchronized at G2/M. Nuclear production of IP3 decreased after silencing of 
PLCβ1. All the experiments were repeated at least three times.
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decrease was related to their iper-activation by PMA, as 
explained elsewhere [35–37], Cyclin B1 down-regulation 
appeared to be related to the amount of PKCs present 
in the cells. In particular, to avoid any oscillation of 
Cyclin B1 expression, all the experiments were performed 
synchronizing the cells at the same cell cycle phase. As 
K562 cell line is characterized by the presence of only 
two DAG-dependent PKC isoforms, PKCα and PKCβII 
[12, 36], we focused on these two molecules. Experiments 
of RNA interference showed that only in PKCα knock-
down conditions the levels of Cyclin B1 drop in the cells. 
This led to an accumulation of the cells at G2/M, which 
could be related to the lack of Cyclin B1 caused by PKCα 
silencing. Indeed, accordingly to literature, a high decrease 
of Cyclin B1 could interfere with the transition through the 
G2/M phase of cell cycle [38]. In addition, this mechanism 
resulted independent by the kinase activity of PKCα. 
Overexpression of a Dominant Negative (DN) mutant of 
PKCα drove to the same up-modulation of Cyclin B1 and 
cell cycle progression than the Wild Type isoform (WT). 
Next, investigating this regulatory mechanism, we found 
that PKCα did not regulate the gene expression of Cyclin 
B1, but it affected its degradation. Notably, experiments 
performed using the proteasome inhibitor MG-132 
indicated that Cyclin B1 degradation raised with lack of 
PKCα. Our findings were supported by p21 up-modulation 
during PKCα silencing. Indeed, the expression of this 
Cip/Kip inhibitor has already been described to increase 
during Cyclin B1 degradation [40]. Next, we decided to 
investigate the behavior of these two molecules during 
cell cycle progression. They resulted able to co-localize 
during the different cell cycle phases, accumulating into 
the nucleus, especially at G2/M. Next, experiments of 
co-immunoprecipitation indicated the possibility 
for the two proteins to interact. In addition, as 
further demonstration of that, PKCα resulted able to 
immunoprecipitated also with cdk1/cdc2, the kinase which 
interacts with Cyclin B1 and regulates G2/M progression of 
the cell cycle [20–28]. In particular, the complex appeared 
to be located in the cytoplasmic fraction and to take place 
along the cell cycle. These evidences suggested a possible 
role for PKCα in preserving Cyclin B1 from degradation 
thanks to its physical interaction with it. Moreover, PKCα 
nuclear translocation during mitosis seemed to modulate 
Cyclin B1 import. Indeed, silencing or overexpression 
of PKCα led to an important modulation of the amount 
of nuclear Cyclin B1. Then, we decided to understand 
which was the factor that promoted PKCα nuclear import 
during mitosis. We observed that nuclear DAG amount, 
as already reported in other models [14–18], raised in 
the nucleus of K562 cells at G2/M. Considering it as the 
possible trigger for PKCα and Cyclin B1 nuclear import, 
we decided to simulate its accumulation using PMA, as 
already described by other studies [41, 42]. This treatment 
increased the accumulation of both PKCα and Cyclin 
B1 in the nuclei of the cells. On the contrary, in order to 
limit DAG production, as Phospholipases C (PLC) are a 
family of proteins able to hydrolyze Phosphatidylinositol 
4,5-bisphosphate (PIP2), producing DAG and IP3  
[44–46], we inhibited their activity treating the cells 
with a PLC inhibitor, U73122. Interestingly, we found a 
minor nuclear accumulation of the two proteins. Next, we 
investigated which PLC isoform could be responsible for 
DAG production during cell cycle progression. Notably, 
we noticed that the only isoform mainly localized in the 
nuclei was PLCβ1, capable to modulate nuclear import of 
PKCα and Cyclin B1 during mitosis. Indeed, silencing this 
isozyme led to the same minor accumulation in the nuclei 
of the two molecules observed using the U73122 inhibitor. 
In particular, Cyclin B1 resulted to be downstream of the 
PLCβ1/PKCα pathway. Indeed, experiments of double 
knock-down of the two molecules did not have any higher 
effect on Cyclin B1 expression than the PKCα silencing 
alone. Finally, we proved that PLCβ1 silencing inhibited 
the production of IP3 in the nucleus of G2/M cells. These 
results indicated that the lipase was responsible of lipid 
changes during cell cycle progression. What emerges by 
our study is a novel mechanism, through which PKCα 
results fundamental for stability and nuclear import of 
Cyclin B1 during G2/M progression. This process is 
mediated by cell cycle related nuclear DAG fluctuations, 
which are due to the activity of nuclear PLCβ1.
MATERIALS AND METHODS
Cell culture
Human erythroleukemia cells (K562) were grown in 
RPMI 1640 (Sigma Aldrich) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and L-glutamine/
streptomycin (1×). Cells were treated with the following 
compounds: Phorbol 12-myristate 13-acetate (PMA, Sigma 
Aldrich) at a final concentration of 50-100nM for 30 mins 
or 16 hours, U73122 (Sigma Aldrich, PLC inhibitor) at 
10 μM for 16 hours, with Go6976 and Go6983 at 1μM 
(Sigma Aldrich, PKC inhibitor) and with 3-(1-(3-imidazol-
1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione 
anilinomonoindolylmaleimide (Calbiochem, PKC inhibitor 
[34]) at 1 μM for 24 hours. Finally, MG-132 (Sigma Aldrich, 
proteasome inhibitor) was used at a final concentration of 
15 μM for 2 hours.
Cell synchronization
Cells were collected as described below for the 
experiments: (1) G1/S cells: proliferating cells were 
cultured in complete RPMI 1640 FBS 10%; (2) G2/M 
blocked cells: growing cells were treated with Nocodazole 
(Sigma Aldrich) at a final concentration of 20 ng/ml for 
16 h; (3) G0/G1 cells: growing cells were starved in 
Hank's Balanced Salt Solution (HBSS, Sigma Aldrich) for 
16 hours. In experiments of PKCα overexpression, cells 
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were partially stimulated to undergo G2/M accumulation 
adding Nocodazole for 6 hours at a final concentration 
of 20ng/ml
Western blot analysis
Cells were collected by centrifugation, washed 
in PBS and lysed in mPER lysis buffer (BIORAD) 
containing protease inhibitors (Thema Ricerca). Samples 
were separated on SDS-PAGE and electro-transferred to 
nitrocellulose membranes. Membranes were washed in 
PBS-0.1%Tween-20 (PBS/T) and nonspecific binding 
sites were blocked by incubation in blocking buffer 
(PBS/T with 5% w/v non-fat dry milk) for 1 h at room 
temperature. After several PBS/T-washes, membranes 
were incubated with primary antibodies overnight at 
4°C. Membranes were washed again, then incubated with 
peroxidase conjugated secondary antibodies diluted in 
PBS/T for 1 h at room temperature. Proteins were detected 
by incubating membranes in enhanced chemiluminescence 
detection system (ECL, Thema Ricerca). Antibodies were 
as follows: PLCβ1, Cyclin D3, Cyclin B1, PKCα, PKCβII, 
Lamin A/C, from Santa Cruz, PKCα and Cyclin B1, 
phospho-Cyclin B1 Ser133, phospho-Cyclin B1 Ser147, 
Cdc25c, Cdk1/cdc2, phospho-Cdk1/cdc2 Tyr15, Cdk7 
from Cell Signaling technology and β-tubulin from 
Sigma Aldrich. Analysis with an antibody for β-tubulin 
demonstrated equal protein loading.
Flow cytometric analysis of cell cycle
For FACS analysis 1 × 106 cells were collected 
by centrifugation at 1,200 rpm for 5 min at 4°C and 
washed twice in ice-cold PBS. Cells were fixed (and 
permeabilized) with −20°C cold 70% ethanol overnight 
at 4°C. Fixed cells were, then, washed in PBS twice and 
resuspended in 1 ml of staining solution (40 μg/ml 
propidium iodide and 100 μg/ml RNase A in PBS). 
The samples were incubated for at least 30 min at room 
temperature in the dark. FACS analysis was performed, 
and the percentage of cells in different phases of the 
cell cycle was assessed using a FC500 flow cytometer 
equipped with cxp software (Beckman Coulter Inc.). At 
least 10,000 events per sample were acquired.
Cell transfections
Cells were transfected with full-length DNA vectors 
for human PKCα (Addgene, plasmid number 21232 and 
21235) [48] using empty pcDNA/2.1 plasmid (Invitrogen) 
as control. Overexpressions were performed using 
Lipofectamine 2000 from Invitrogen. Cells were seeded at 
a cell density of 5 × 105/ml in 6-well plates, to which was 
added the mix of Lipofectamine 2000 (Life Technologies) 
and right vectors, following manufacturer’s instructions. 
The expression of PKCα, PKCβII and PLCβ1 was 
silenced by RNAi at a final concentration of 50nM using 
the electroporation assay kit by Thema Ricerca (program 
T-16) and Lipofectamine RNAiMAX (Life Technologies) 
as indicated by the manufacturers’ instructions. The 
following siRNAs were used: in order to silence PLCβ1 
s23358 and s23359 (Applied Biosystems), to silence 
PKCα s11092, s11093 and s11094 (Applied Biosystems), 
to silence PKCβII s11095 (Applied Biosystems). As 
negative control a mix of Silencer Select Negative Control 
#1 and #2 siRNAs (Applied Biosystems).
Nuclear extraction and purification
Cells were collected, centrifuged and washed in 
PBS 1X. PBS 1X was accurately removed, and the pellets 
were resuspended in 1ml of TM2 buffer (10 mM Tris-HCl 
pH 7.4, 2 mM MgCl2) for 2 minutes. Then, Triton 0.6% 
was added and everything was passed twice through a 
syringe with a 22 ½ gauge needle. Next, MgCl2 3mM was 
added to the solution, which was centrifuged for 10 mins 
at 0.8 rpm. The nuclear pellets were washed twice in TM5 
buffer (10 mM Tris-HCl pH 7.4, 5 mM MgCl2), while the 
supernatant was transferred in a new vial and used like a 
cytoplasmic control.
Immunoprecipitation
Cells were lysed in mPER lysis buffer (BIORAD) 
containing protease inhibitors (Thema Ricerca). 500 μg 
of proteins were pre-cleared adding 20μl of Protein A/G 
PLUS-Agarose (Santa Cruz) for 1 hour at 4°C. Then, 
beads were centrifuged and the supernatant transferred in 
another vial. 500 μl of protein lysates were incubated over/
night with the appropriate primary antibodies on wheels at 
4°C. The day after, 25 μl of Protein A/G PLUS-Agarose 
were added for 1h at 4°C. Beads were centrifuged and 
pellets washed 3 times with mPER. Immuno-complexes 
were resuspended in loading buffer (4X), boiled at 95°C 
for 5 minutes, resolved on SDS/PAGE and transferred 
on nitrocellulose. After incubation with the indicated 
antibodies, antibody–protein interactions were detected 
with enhanced chemiluminescence detection system (ECL, 
Thema Ricerca). As positive control 50 μg of proteins 
from total lysates of K562 were loaded on SDS/PAGE gel.
Immunofluorescence microscopy
Cells were seeded on electrostatically charged 
glass slides using a Shandon Cytospin (Thermo Electron 
Corporation, Pittsburgh, PA, USA) at low acceleration 
and 200 rpm for 5 min. Slides were fixed in 4% 
paraformaldehyde at 37°C for 10 min and permeabilized 
with 0.15% Triton X-100 in PBS for 8 min. Then 
slides were blocked with PBS containing 5% BSA 
for 1 h. Incubation with monoclonal anti-PKCα (1:100) 
(Santa Cruz) and Cyclin B1 (1:100) (Santa Cruz) was 
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performed overnight at 4°C in blocking medium and 
then with FITC-conjugated anti-mouse immunoglobulin 
G (IgG) antibody (1:200) or Cy3-conjugated anti-rabbit 
IgG antibody (1:100) (Sigma-Aldrich) for 1 h at room 
temperature. Slides were washed 3 times for 10 min at 
room temperature with PBS/Tween and mounted with a 
DAPI anti-fade reagent in glycerol (Molecular Probes, 
Eugene, OR, USA). Images were taken on a Zeiss Axio 
ImagerZ1 microscope, equipped with 60X/NA 1.4 optics 
and Apotome apparatus, coupled to a computer driven 
Zeiss AxioCam digital camera (MRm), using Zeiss Axio 
Vision 4.4 software (Carl Zeiss, Oberkochen, Germany).
RNA extraction, retrotranscription  
and real-time PCR analysis
RNA extraction, retrotranscription and real-time 
PCR were performed as already described [12]. Gene 
expression were assessed using for PKCα the probe 
Hs00925193_m1, for Cyclin B1 the Hs00820463_g1 and 
for PLCβ1 the Hs00248563_m1 (Applied Biosystems).
Cell Counting
To determine cell growth, cells were synchronized 
using Nocodazole and, 24 hours later, the block was 
removed seeding them in complete RPMI 10% FBS at a 
cell density of 1 × 105/ml in 6-well plates. Growth curves 
were determined by direct counting of cells harvested for 
24, 48 and 72 h after seeding. Viable cells were handly 
counted by a hemocytometer using 0.2% Trypan Blue.
Statistical analysis
Statistical analyses were performed by Student 
t-test, using GraphPad Prism (GraphPad Software Inc. 
version.6) (*P < 0.05, **P < 0.001, ***P < 0.0001).
Quantification of DAG amount
K562 cells were cultured and synchronized 
as previously described. Nuclei or intact cells were 
labeled with [3H]-glycerol (10 μCi/ml/1 × 106 cells) for 
90 minutes. Next, nuclei and total cells were precipitated 
with 10% TCA and, then, 10 volumes of chloroform/
methanol/concentrated HCl (300:300:1.5) were added and 
lipids extracted for 20 hours at 4°C. After centrifugation, 
supernatants were preserved and the pellets were 
re-extracted twice with 10 volumes of chloroform/
methanol/concentrated HCl (400:200/1.5). The combined 
supernatants were dried under steam of nitrogen and 
lipids were dissolved in 100ul of chloroform and washed 
three times in 4 volumes of chloroform/methanol/water 
(3:48:47). Finally the samples were dried under a steam of 
nitrogen and [3H]-labelled lipids were analyzed by TLC 
on silica gel 60 plates developed with ether/exane/NH4 
(50:50:0.25). TLC plates were sprayed with Enhancer 
(Du Pont, NEN) and fluorographed at −80°C. Spots 
corresponding to lipids were scraped off, extracted with 
1.5 ml of 0.6N HCl-Methanol (60:40 by volume) for 
48 hours with gentle stirring and counted with a liquid 
scintillation counter using 9ml of Packard Pico-Fluor 40 
scintillation cocktail.
PLC assay
The activity of nuclear PLCβ1 was assessed using a 
protocol described elsewhere [46].
ACKNOWLEDGEMENTS
This work was supported by Italian MIUR-FIRB, 
Human Proteome Net.
Conflict of interest
The authors declare no conflict of interest.
ABBREVIATIONS
PKC, Protein Kinase C; PLC, Phospholipase C; 
DAG, diacylglycerol; IP3, inositol 1,4,5-trisphosphate; 
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